Silver Book Fact

Vaccines in development 2013

Fact image

Vaccines in development for 2013

Pharmaceutical Researchers and Manufacturers of America. Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines. Washington, D.C.: PhRMA; 2013. http://phrma.org/medicines-in-development-for-vaccines-2013

Reference

Title
Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines
Publisher
PhRMA
Publication Date
2013
Authors
Pharmaceutical Researchers and Manufacturers of America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Cost of measles much higher than vaccine
    One case of measles can cost 23 times as much as a single vaccination to prevent it.  
  • Vaccines in development 2013
    137 vaccines are currently in development in the U.S. for infectious diseases.  
  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.